Continuing experiments will test whether the transplanted cells will continue to function and thrive without additional anti-CD154 administration. The researchers hope to replicate this successful experiment in humans, the New York Times reported, but details of when human trials will begin are as yet unavailable. The National Institutes of Health and the drug's manufacturer, Biogen Inc. of Cambridge, Mass., will fund the trials. Paper including authors N.S. Kenyon and C. Ricordi forthcoming later this year in the Proceedings of the National Academy of Sciences, which approved early release of paper on June 2, 1999.
Coverage includes biomedicine, behavior, conservation and veterinary science.
Primate-Science Research Highlights are supported by a grant from the National Institutes of Health, National Center for Research Resources. Copyright 1999, Wisconsin Regional Primate Research Center. No portion of this highlight may be copied or redistributed without the consent of the editor.